| Ceramide: second messenger or modulator of membrane structure and dynamics? WJ BLITTERSWIJK, AH LUIT, RJ Veldman, M Verheij, J Borst Biochemical Journal 369 (2), 199-211, 2003 | 541 | 2003 |
| Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis C Gajate, E del Canto-Jañez, AU Acuña, F Amat-Guerri, E Geijo, ... The Journal of experimental medicine 200 (3), 353-365, 2004 | 254 | 2004 |
| Accumulation of glycosphingolipids in Niemann-Pick C disease disrupts endosomal transport D te Vruchte, E Lloyd-Evans, RJ Veldman, DCA Neville, RA Dwek, ... Journal of Biological Chemistry 279 (25), 26167-26175, 2004 | 234 | 2004 |
| Sphingolipid mediators in cardiovascular cell biology and pathology T Levade, N Augé, RJ Veldman, O Cuvillier, A Nègre-Salvayre, ... Circulation research 89 (11), 957-968, 2001 | 229 | 2001 |
| Elevation of glucosylceramide in multidrug‐resistant cancer cells and accumulation in cytoplasmic droplets H Morjani, N Aouali, R Belhoussine, RJ Veldman, T Levade, M Manfait International journal of cancer 94 (2), 157-165, 2001 | 158 | 2001 |
| A neutral sphingomyelinase resides in sphingolipid-enriched microdomains and is inhibited by the caveolin-scaffolding domain: potential implications in tumour necrosis factor … RJ VELDMAN, N MAESTRE, OM ADUIB, JA MEDIN, R SALVAYRE, ... Biochemical Journal 355 (3), 859-868, 2001 | 131 | 2001 |
| The involvement of sphingolipids in multidrug resistance H Sietsma, RJ Veldman, JW Kok The Journal of membrane biology 181, 153-162, 2001 | 118 | 2001 |
| Altered sphingolipid metabolism in multidrug‐resistant ovarian cancer cells is due to uncoupling of glycolipid biosynthesis in the Golgi apparatus RJ Veldman, K Klappe, J Hinrichs, INA Hummel, G Van Der Schaaf, ... The FASEB Journal 16 (9), 1111-1113, 2002 | 117 | 2002 |
| Differential expression of sphingolipids in MRP1 overexpressing HT29 cells JW Kok, RJ Veldman, K Klappe, H Koning, CM Filipeanu, M Müller International journal of cancer 87 (2), 172-178, 2000 | 102 | 2000 |
| 1-phenyl-2-decanoylamino-3-morpholino-1-propanol chemosensitizes neuroblastoma cells for taxol and vincristine H Sietsma, RJ Veldman, D Kolk, B Ausema, W Nijhof, W Kamps, ... Clinical cancer research 6 (3), 942-948, 2000 | 90 | 2000 |
| Enriching lipid nanovesicles with short‐chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors M van Lummel, WJ van Blitterswijk, SR Vink, RJ Veldman, ... The FASEB Journal 25 (1), 280-289, 2011 | 64 | 2011 |
| N-hexanoyl-sphingomyelin potentiates in vitro doxorubicin cytotoxicity by enhancing its cellular influx RJ Veldman, S Zerp, WJ Van Blitterswijk, M Verheij British journal of cancer 90 (4), 917-925, 2004 | 64 | 2004 |
| The absence of functional glucosylceramide synthase does not sensitize melanoma cells for anticancer drugs RJ Veldman, A Mita, O Cuvillier, V Garcia, K Klappe, JA Medin, ... The FASEB journal 17 (9), 1144-1146, 2003 | 58 | 2003 |
| Structural requirements for catalysis and membrane targeting of mammalian enzymes with neutral sphingomyelinase and lysophospholipid phospholipase C activities: analysis by … F Rodrigues-Lima, AC Fensome, M Josephs, J Evans, RJ Veldman, ... Journal of Biological Chemistry 275 (36), 28316-28325, 2000 | 56 | 2000 |
| Metabolism and apoptotic properties of elevated ceramide in HT29rev cells RJ VELDMAN, K KLAPPE, D HOEKSTRA, JW KOK Biochemical Journal 331 (2), 563-569, 1998 | 55 | 1998 |
| Ara‐C‐and daunorubicin‐induced recruitment of Lyn in sphingomyelinase‐enriched membrane rafts S Grazide, N Maestre, RJ Veldman, C Bezombes, S Maddens, T Levade, ... The FASEB Journal 16 (12), 1685-1687, 2002 | 52 | 2002 |
| ABCA1-dependent but apoA-I-independent cholesterol efflux mediated by fatty acid–bile acid conjugates (FABACs) I Goldiner, AE van der Velde, KE Vandenberghe, MA van Wijland, ... Biochemical journal 396 (3), 529-536, 2006 | 38 | 2006 |
| Coformulated N-octanoyl-glucosylceramide improves cellular delivery and cytotoxicity of liposomal doxorubicin RJ Veldman, GA Koning, A van Hell, S Zerp, SR Vink, G Storm, M Verheij, ... Journal of Pharmacology and Experimental Therapeutics 315 (2), 704-710, 2005 | 38 | 2005 |
| Enhanced conversion of triglyceride-rich lipoproteins and increased low-density lipoprotein removal in LPLS447X carriers MC Nierman, BH Prinsen, J Rip, RJ Veldman, JA Kuivenhoven, ... Arteriosclerosis, thrombosis, and vascular biology 25 (11), 2410-2415, 2005 | 36 | 2005 |
| Inhibition of P-glycoprotein activity and chemosensitization of multidrug-resistant ovarian carcinoma 2780AD cells by hexanoylglucosylceramide RJ Veldman, H Sietsma, K Klappe, D Hoekstra, JW Kok Biochemical and biophysical research communications 266 (2), 492-496, 1999 | 25 | 1999 |
